71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial.
Saved in:
| Title: | 71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial. |
|---|---|
| Authors: | Bentebibel, S-E.1 (AUTHOR), McGrail, D.2 (AUTHOR), Wahab, R. Abdel1 (AUTHOR), Kochat, V.3 (AUTHOR), Arslan, E.3 (AUTHOR), Pazdrak, B.1 (AUTHOR), Tahon, N.H.4 (AUTHOR), Amaria, R.N.1 (AUTHOR), Glitza, I.C.1 (AUTHOR), Patel, S.1 (AUTHOR), Wong, M.K.K.1 (AUTHOR), Tawbi, H.A.1 (AUTHOR), Mcquade, J.1 (AUTHOR), Davies, M.1 (AUTHOR), Bernatchez, C.1 (AUTHOR), Burks, J.5 (AUTHOR), Rai, K.3 (AUTHOR), Ekmekcioglu, S.1 (AUTHOR), Lizée, L.1 (AUTHOR), Diab, A.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS242-S242. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.079 |
